Bliss GVS Pharma Ltd - 506197 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed herewith Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2021. This is for your information and record. BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window
This is to inform you that pursuant to Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ('the Company') will remain closed for Insiders, Designated Persons and their immediate relatives of the Company with effect from Thursday, July 01, 2021 until 48 hours after the announcement of the Unaudited financial results of the Company for the quarter ended June 30, 2021. BLISS GVS PHARMA LTD. - 506197 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed disclosure of Related Party Transactions on the basis on consolidated financial statements for the half year ended March 31, 2021. Kindly take the above information on record. Bliss GVS Pharma Ltd - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Polus Global Fund Bliss GVS Pharma Ltd - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement of Audited Financial Results of the Company for the quarter and year ended March 31, 2021 published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshkati' a Regional Daily, on May 13, 2021. Kindly take the same on record. Bliss GVS Pharma Ltd - 506197 - Contact Details Of Kmps For Reporting Of Material Events
In terms of Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Mr. Gagan Sharma Managing Director & Key Managerial Personal ('KMP') and Mr. Vipul Thakkar, Chief Financial Officer & Key Managerial Personal ('KMP') of the Company hereby authorized for the purpose of determining materiality of an event or information and Ms. Aditi Bhatt Company Secretary and Key Managerial Personal ('KMP') of the Company have been authorized to make disclosure of information as mentioned above to the Stock Exchanges. The details of KMP's authorized for the said purpose is enclosed herewith. Bliss GVS Pharma Ltd - 506197 - Declaration Of Not Debarred From Holding The Office Of Director For Appointment Of Mr. Gagan Harsh Sharma As MD & Re-Appointment Of Mr. Santosh Parab As ID
With reference to our earlier intimation of Outcome of Board Meeting made to your good office ('BSE & NSE') on 11th May, 2021, regarding Appointment of Mr. Gagan Harsh Sharma as Managing Director and Re-appointment of Mr. Santosh Parab as Non-Executive Independent Director of the Company. This is to inform you that, while considering the appointment of Mr. Gagan Harsh Sharma as Managing Director and Re-appointment of Mr. Santosh Parab as Non-Executive Independent Director, the Nomination and Remuneration Committee & Board of Directors of the Company has verified and confirmed from them that they are not debarred from holding the office of Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that, Mr. Gagan Harsh Sharma being appointed as Managing Director and Mr. Santosh Parab appointed as Non-Executive Independent Director are not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment
Issue & Allotment of 2,10,500 Equity Shares of face value of Rs. 1 each of the Company under 'Bliss GVS Pharma Limited-Employee Stock Option Plan 2019''. BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Dividend Updates
Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2021, subject to approval of the shareholders in the forthcoming Annual General Meeting of the Company.